EP1402262A4 - MAP3Ks ALS MODIFIZIERER DES p53-WEGS UND VERWENDUNGSVERFAHREN - Google Patents
MAP3Ks ALS MODIFIZIERER DES p53-WEGS UND VERWENDUNGSVERFAHRENInfo
- Publication number
- EP1402262A4 EP1402262A4 EP02741809A EP02741809A EP1402262A4 EP 1402262 A4 EP1402262 A4 EP 1402262A4 EP 02741809 A EP02741809 A EP 02741809A EP 02741809 A EP02741809 A EP 02741809A EP 1402262 A4 EP1402262 A4 EP 1402262A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- map3ks
- modifier
- pathway
- methods
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/527—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving lyase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57449—Specifically defined cancers of ovaries
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4739—Cyclin; Prad 1
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/82—Translation products from oncogenes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/988—Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2510/00—Detection of programmed cell death, i.e. apoptosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Food Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29607601P | 2001-06-05 | 2001-06-05 | |
US296076P | 2001-06-05 | ||
US32860501P | 2001-10-10 | 2001-10-10 | |
US328605P | 2001-10-10 | ||
US35725302P | 2002-02-15 | 2002-02-15 | |
US357253P | 2002-02-15 | ||
US36119602P | 2002-03-01 | 2002-03-01 | |
US361196P | 2002-03-01 | ||
PCT/US2002/017457 WO2002098889A2 (en) | 2001-06-05 | 2002-06-03 | MAP3Ks AS MODIFIER OF THE p53 PATHWAY AND METHODS OF USE |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1402262A2 EP1402262A2 (de) | 2004-03-31 |
EP1402262A4 true EP1402262A4 (de) | 2005-05-11 |
Family
ID=27501675
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP02741809A Withdrawn EP1402262A4 (de) | 2001-06-05 | 2002-06-03 | MAP3Ks ALS MODIFIZIERER DES p53-WEGS UND VERWENDUNGSVERFAHREN |
EP02732039A Withdrawn EP1402051A4 (de) | 2001-06-05 | 2002-06-03 | Lces als modifikatoren des p53-wegs und verwendungsverfahren |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP02732039A Withdrawn EP1402051A4 (de) | 2001-06-05 | 2002-06-03 | Lces als modifikatoren des p53-wegs und verwendungsverfahren |
Country Status (5)
Country | Link |
---|---|
EP (2) | EP1402262A4 (de) |
JP (2) | JP2004532638A (de) |
AU (1) | AU2002314887A1 (de) |
CA (2) | CA2448112A1 (de) |
WO (4) | WO2002098891A2 (de) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2012233044B2 (en) * | 2002-11-22 | 2015-09-03 | Ganymed Pharmaceuticals Ag | Genetic products differentially expressed in tumors and the use thereof |
DE10254601A1 (de) * | 2002-11-22 | 2004-06-03 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
AU2003297318A1 (en) * | 2002-12-20 | 2004-07-22 | Millennium Pharmaceuticals, Inc. | Methods and compositions for treating cancer using 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 21617, 39228, 49928, 54476. |
DE10316701A1 (de) * | 2003-04-09 | 2004-11-04 | Hinzmann, Bernd, Dr. | Humane Nukleinsäuresequenzen aus Bronchialkarzinomen |
JPWO2005005665A1 (ja) * | 2003-07-11 | 2006-11-09 | 萬有製薬株式会社 | Lceによる肥満治療に有効な化合物の評価方法 |
WO2005023186A2 (en) * | 2003-09-04 | 2005-03-17 | Immusol Inc. | Methods of identifying agents that inhibit the growth of cancer cells |
WO2005083425A2 (en) * | 2004-02-26 | 2005-09-09 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with mitogen-activated protein kinase kinase kinase 13 (map3k13) |
EP2650905B1 (de) | 2004-06-04 | 2022-11-09 | The Board of Trustees of the University of Illinois | Verfahren und Einrichtungen zum Herstellen und Zusammenbauen von druckbaren Halbleiterelementen |
KR101610885B1 (ko) | 2007-01-17 | 2016-04-08 | 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 | 프린팅기반 어셈블리에 의해 제조되는 광학 시스템 |
US8865489B2 (en) | 2009-05-12 | 2014-10-21 | The Board Of Trustees Of The University Of Illinois | Printed assemblies of ultrathin, microscale inorganic light emitting diodes for deformable and semitransparent displays |
US9442285B2 (en) | 2011-01-14 | 2016-09-13 | The Board Of Trustees Of The University Of Illinois | Optical component array having adjustable curvature |
US9765934B2 (en) | 2011-05-16 | 2017-09-19 | The Board Of Trustees Of The University Of Illinois | Thermally managed LED arrays assembled by printing |
EP2713863B1 (de) | 2011-06-03 | 2020-01-15 | The Board of Trustees of the University of Illionis | Anpassbare aktiv multiplexierte elektrodenanordnung mit hochdichter oberfläche zur elektrophysiologischen messung am gehirn |
WO2013089867A2 (en) | 2011-12-01 | 2013-06-20 | The Board Of Trustees Of The University Of Illinois | Transient devices designed to undergo programmable transformations |
CN114181944B (zh) * | 2020-09-14 | 2023-10-03 | 中国科学院动物研究所 | 突变基因及构建短肢性侏儒症小型猪模型的方法和用途 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994024159A1 (en) * | 1993-04-15 | 1994-10-27 | National Jewish Center For Immunology And Respiratory Medicine | Method and product for regulating cell responsiveness to external signals |
WO1999041385A1 (en) * | 1998-02-13 | 1999-08-19 | Cadus Pharmaceutical Corporation | Mekk1 proteins and fragments thereof for use in regulating apoptosis |
WO1999047686A2 (en) * | 1998-03-16 | 1999-09-23 | Cadus Pharmaceutical Corporation | Human mekk proteins, corresponding nucleic acid molecules, and uses therefor |
WO2002014355A2 (en) * | 2000-08-11 | 2002-02-21 | Merck Patent Gmbh | Novel mitogen activated kinase |
WO2002096943A1 (en) * | 2001-05-25 | 2002-12-05 | Asahi Kasei Kabushiki Kaisha | Stat6-activating genes |
WO2003091419A2 (en) * | 2002-04-24 | 2003-11-06 | Incyte Corporation | Kinases and phosphatases |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0572478B1 (de) * | 1991-02-22 | 2005-09-07 | The Walter And Eliza Hall Institute Of Medical Research | Hbgad und higad polypeptide und nukleinsäuren und deren verwendung zur diagnose und behandlung von gad autoantigen assoziierten krankheiten |
US5554523A (en) * | 1994-03-01 | 1996-09-10 | Children's Hospital Of Philadelphia | Nucleic acid sequences encoding human leucine-zipper protein-kinase |
JP2002538826A (ja) * | 1999-03-18 | 2002-11-19 | ザ ユニバーシティ オブ ブリストル | カエノラブジチス・エレガンス由来の多飽和脂肪酸(pufa)エロンガーゼ |
WO2000065054A2 (en) * | 1999-04-23 | 2000-11-02 | Incyte Genomics, Inc. | Human membrane-associated proteins |
WO2001007586A2 (en) * | 1999-07-22 | 2001-02-01 | The University Of British Columbia | A plant long chain fatty acid biosynthetic enzyme |
CA2390421A1 (en) * | 1999-11-12 | 2001-05-17 | Human Genome Sciences, Inc. | 24 human secreted proteins |
US6436703B1 (en) * | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
AU2001270045A1 (en) * | 2000-06-20 | 2002-01-02 | Incyte Genomics, Inc. | Secreted proteins |
EP1341920A2 (de) * | 2000-11-29 | 2003-09-10 | Xenon Genetics, Inc. | Menschliche elongasengene und ihre verwendungen |
WO2002063006A2 (en) * | 2001-02-06 | 2002-08-15 | Incyte Genomics, Inc. | Receptors and membrane-associated proteins |
WO2002062975A2 (en) * | 2001-02-08 | 2002-08-15 | Bayer Aktiengesellschaft | Regulation of human elongase hselo1-like protein |
AU2002247691A1 (en) * | 2001-02-08 | 2002-08-19 | Bayer Aktiengesellschaft | Regulation of human elongase hselo1-like protein |
-
2002
- 2002-06-03 CA CA002448112A patent/CA2448112A1/en not_active Abandoned
- 2002-06-03 WO PCT/US2002/017465 patent/WO2002098891A2/en not_active Application Discontinuation
- 2002-06-03 CA CA002449479A patent/CA2449479A1/en not_active Abandoned
- 2002-06-03 EP EP02741809A patent/EP1402262A4/de not_active Withdrawn
- 2002-06-03 EP EP02732039A patent/EP1402051A4/de not_active Withdrawn
- 2002-06-03 JP JP2003502009A patent/JP2004532638A/ja not_active Withdrawn
- 2002-06-03 AU AU2002314887A patent/AU2002314887A1/en not_active Abandoned
- 2002-06-03 JP JP2003502178A patent/JP2005514906A/ja not_active Withdrawn
- 2002-06-03 WO PCT/US2002/017460 patent/WO2002098468A1/en not_active Application Discontinuation
- 2002-06-03 WO PCT/US2002/017739 patent/WO2002099068A2/en not_active Application Discontinuation
- 2002-06-03 WO PCT/US2002/017457 patent/WO2002098889A2/en not_active Application Discontinuation
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994024159A1 (en) * | 1993-04-15 | 1994-10-27 | National Jewish Center For Immunology And Respiratory Medicine | Method and product for regulating cell responsiveness to external signals |
WO1999041385A1 (en) * | 1998-02-13 | 1999-08-19 | Cadus Pharmaceutical Corporation | Mekk1 proteins and fragments thereof for use in regulating apoptosis |
WO1999047686A2 (en) * | 1998-03-16 | 1999-09-23 | Cadus Pharmaceutical Corporation | Human mekk proteins, corresponding nucleic acid molecules, and uses therefor |
WO2002014355A2 (en) * | 2000-08-11 | 2002-02-21 | Merck Patent Gmbh | Novel mitogen activated kinase |
WO2002096943A1 (en) * | 2001-05-25 | 2002-12-05 | Asahi Kasei Kabushiki Kaisha | Stat6-activating genes |
WO2003091419A2 (en) * | 2002-04-24 | 2003-11-06 | Incyte Corporation | Kinases and phosphatases |
Non-Patent Citations (3)
Title |
---|
AGARWAL M L ET AL: "Regulation of p53 expression by the RAS-MAP kinase pathway.", ONCOGENE. 3 MAY 2001, vol. 20, no. 20, 3 May 2001 (2001-05-03), pages 2527 - 2536, XP002306482, ISSN: 0950-9232 * |
DATABASE WPI Section Ch Week 200313, Derwent World Patents Index; Class B04, AN 2003-140442, XP002306484 * |
LEE S W ET AL: "Sustained activation of Ras/Raf/mitogen-activated protein kinase cascade by the tumor suppressor p53.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 18 JUL 2000, vol. 97, no. 15, 18 July 2000 (2000-07-18), pages 8302 - 8305, XP002306483, ISSN: 0027-8424 * |
Also Published As
Publication number | Publication date |
---|---|
WO2002098891A2 (en) | 2002-12-12 |
WO2002099068A2 (en) | 2002-12-12 |
WO2002098889A3 (en) | 2003-03-27 |
EP1402051A4 (de) | 2005-08-17 |
WO2002099068A3 (en) | 2003-12-04 |
CA2449479A1 (en) | 2002-12-12 |
JP2005514906A (ja) | 2005-05-26 |
WO2002098468A1 (en) | 2002-12-12 |
EP1402262A2 (de) | 2004-03-31 |
JP2004532638A (ja) | 2004-10-28 |
EP1402051A2 (de) | 2004-03-31 |
AU2002314887A1 (en) | 2002-12-16 |
WO2002098889A2 (en) | 2002-12-12 |
WO2002098891A3 (en) | 2003-05-30 |
CA2448112A1 (en) | 2002-12-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1572890A4 (de) | Slc7s als modifikatoren des p53-wegs und verwendungsverfahren | |
EP1421384A4 (de) | Hprp4s als modifikatoren des p53-wegs sowie verwendungsverfahren | |
AU2003224638A8 (en) | Pdpk1s as modifiers of the p53 pathway and methods of use | |
HK1078266A1 (en) | Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and the use of the same | |
AU2002219135A1 (en) | Substituted 2-anilino-benzimidazoles and the use thereof as NHE-inhibitors | |
EP1402262A4 (de) | MAP3Ks ALS MODIFIZIERER DES p53-WEGS UND VERWENDUNGSVERFAHREN | |
MXPA03007126A (es) | Composiciones parasiticidas y metodos de uso. | |
AU2002239933A1 (en) | Antineoplastic polyalkoxyalkylsiloxanes and methods of use thereof | |
AU2002337916A1 (en) | Modifier of the p53 pathway and methods of use | |
EP1418194A4 (de) | Modifiziertes polyalkylenimin und verfahren zu seiner verwendung | |
AU2002343100A1 (en) | The use of metal-chelating adsorbents | |
AU2001233588A1 (en) | New toralactone and its derivation and the use of decreasing blood-fat and losing weight | |
AU2002256967A1 (en) | Treating or reducing the risk of cardiovascular disease | |
AU2002360586A8 (en) | Flj1115 as modifier of the apaf-1 pathway and methods of use | |
AU2003303094A8 (en) | Mat2as as modifiers of the p53 pathway and methods of use | |
AU2002357817A8 (en) | Klcs as modifiers of the p53 pathway and methods of use | |
AU2002312283A1 (en) | Srpks as modifiers of the p53 pathway and methods of use | |
AU2002303947A1 (en) | Pecis as modifiers of the p53 pathway and methods of use | |
AU2002345486A1 (en) | Slc13as as modifiers of the p53 pathway and methods of use | |
AU2002303951A1 (en) | Glras as modifiers of the p53 pathway and methods of use | |
AU2002314874A1 (en) | Modifiers of the p53 pathway and methods of use | |
AU2002332130A1 (en) | Msrebps as modifiers of the srebp pathway and methods of use | |
AU2002361654A1 (en) | Mbcats as modifiers of the beta-catenin pathway and methods of use | |
AU2002333371A1 (en) | Novel 4-aminofuropyrimidines and the use thereof | |
AU2003278811A8 (en) | Ldlrs as modifiers of the p53 pathway and methods of use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20031219 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: 7G 01N 33/50 B Ipc: 7A 61K 38/00 B Ipc: 7G 01N 33/53 A |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20050321 |
|
17Q | First examination report despatched |
Effective date: 20050504 |
|
17Q | First examination report despatched |
Effective date: 20050504 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20070402 |